1. Home
  2. DFIN vs STOK Comparison

DFIN vs STOK Comparison

Compare DFIN & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DFIN
  • STOK
  • Stock Information
  • Founded
  • DFIN 1983
  • STOK 2014
  • Country
  • DFIN United States
  • STOK United States
  • Employees
  • DFIN N/A
  • STOK N/A
  • Industry
  • DFIN Other Consumer Services
  • STOK Biotechnology: Pharmaceutical Preparations
  • Sector
  • DFIN Consumer Discretionary
  • STOK Health Care
  • Exchange
  • DFIN Nasdaq
  • STOK Nasdaq
  • Market Cap
  • DFIN 1.4B
  • STOK 1.3B
  • IPO Year
  • DFIN N/A
  • STOK 2019
  • Fundamental
  • Price
  • DFIN $50.29
  • STOK $31.35
  • Analyst Decision
  • DFIN Strong Buy
  • STOK Strong Buy
  • Analyst Count
  • DFIN 3
  • STOK 7
  • Target Price
  • DFIN $70.67
  • STOK $30.83
  • AVG Volume (30 Days)
  • DFIN 270.3K
  • STOK 1.4M
  • Earning Date
  • DFIN 10-29-2025
  • STOK 11-12-2025
  • Dividend Yield
  • DFIN N/A
  • STOK N/A
  • EPS Growth
  • DFIN N/A
  • STOK N/A
  • EPS
  • DFIN 2.79
  • STOK 0.91
  • Revenue
  • DFIN $755,000,000.00
  • STOK $199,893,000.00
  • Revenue This Year
  • DFIN N/A
  • STOK $416.54
  • Revenue Next Year
  • DFIN $4.66
  • STOK N/A
  • P/E Ratio
  • DFIN $18.55
  • STOK $34.83
  • Revenue Growth
  • DFIN N/A
  • STOK 1218.82
  • 52 Week Low
  • DFIN $37.80
  • STOK $5.35
  • 52 Week High
  • DFIN $69.93
  • STOK $38.69
  • Technical
  • Relative Strength Index (RSI)
  • DFIN 42.31
  • STOK 59.92
  • Support Level
  • DFIN $50.63
  • STOK $31.47
  • Resistance Level
  • DFIN $55.35
  • STOK $33.88
  • Average True Range (ATR)
  • DFIN 1.73
  • STOK 2.41
  • MACD
  • DFIN -0.05
  • STOK -0.52
  • Stochastic Oscillator
  • DFIN 4.37
  • STOK 32.86

About DFIN Donnelley Financial Solutions Inc.

Donnelley Financial Solutions Inc is a risk and compliance solutions company. The company provides regulatory filing and deal solutions via its software-as-a-service, technology-enabled services, and print and distribution solutions to public and private companies, mutual funds, and other regulated investment firms. The company operates in four segments: Capital Markets - Software Solutions, Capital Markets - Compliance and Communications Management, Investment Companies - Software Solutions and Investment Companies - Compliance and Communications Management. Its geographical segments are the United States( USA), Europe, Asia, Canada, and others, of which the USA accounts for the vast majority of its total revenue.

About STOK Stoke Therapeutics Inc.

Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.

Share on Social Networks: